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OBJECTIVES: The objective of this study is to review the literature on the rate and 
impact of infusion reactions (IR) associated with anti-EGFR monoclonal antibody 
(MoAb) therapies for the treatment of metastatic colorectal cancer (mCRC). 
METHODS: This review searched PubMed, FDA web site, Medscape, and package 
inserts (PI) for studies reporting IR rates and their clinical or economic impact associ-
ated with cetuximab or panitumumab in mCRC patients. Both clinical trials and 
observational studies published in English by October 2009 were included. RESULTS: 
A total of 16 studies were reviewed. For patients receiving cetuximab, across all 
studies, rates of all-grade IRs ranged from 4% to 32%; and rates of severe IRs were 
0.5%-22%. For patients receiving panitumumab, rates of all-grade IRs ranged from 
0% to 4%; and rates of severe IRs were from 0%-1.0%. Among patients who received 
cetuximab and experienced a severe IR, 34%–50% discontinued cetuximab therapy. 
Only one study evaluated the resource utilization and costs associated with IRs in 
patients treated with cetuximab. Mean incremental costs were $9308 to treat cetux-
imab associated IRs that resulted in an emergency room visit or hospitalization and 
$1725 for those that required outpatient treatment. Several studies reported substan-
tial burden on health care providers, patients, and caregivers when IRs occurred. 
Patients with IRs required 31%-80% more staff time to observe and manage these 
events. No study reported economic impact of severe IRs associated with panitu-
mumab. CONCLUSIONS: A greater range in the rate of severe IRs associated with 
cetuximab treatment was reported in the literature than that for panitumumab. Severe 
IRs often require costly intensive medical intervention and can cause disruption or 
discontinuation of therapy.
PCN21
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OBJECTIVES: Triple negative breast cancer (TNBC), characterized by lack of estrogen 
and progesterone receptors, and HER2 not being over-expressed, does not respond to 
standard therapies, and exhibits more aggressive clinical behavior. The objective of 
this study was to assess the clinical outcomes of TNBC patients compared to other 
types of BC in a US local community practice. METHODS: A retrospective analysis 
was conducted using the Georgia Cancer Specialist Database (2003–2008). Patients 
with BC and conﬁrmed TN/non-TN status were selected. For stage I-III patients, the 
outcomes were disease-free survival (DFS) and recurrence. For stage IV patients, 
the outcome was overall survival (OS). Kaplan-Meier curves were used to compare 
the event rates between TN and non-TN groups. The impact of TN status on the 
outcomes was examined with multivariate Cox models adjusting for demographic and 
clinical characteristics. RESULTS: There were 1572 stage I-III patients with 26.3% 
(n = 414) being TN and 245 stage IV with 25.7% (n = 63) TN. For stage I-III, TN 
group had signiﬁcantly lower rate for 5-year DFS (76.8% vs. 89.0%) and higher rate 
for 5-year recurrence (18.8% vs. 11.2%), compared to non-TN group (all p < 0.001). 
The adjusted results demonstrated signiﬁcant association between TN status and lower 
likelihood of DFS (HR = 0.37) and higher risk for recurrence (HR = 2.85), both p < 
0.0001. For stage IV, TN group was found to have signiﬁcantly shorter Median OS 
(405 vs. 847 days, P = 0.0003). The adjusted results showed TN status was associated 
with high risk of mortality (HR = 2.20, p = 0.0004). CONCLUSIONS: Based on data 
from a US local oncology practice, this study demonstrated inferior clinical outcomes 
for TNBC compared to other types of BC. The results highlight the need for better 
understanding and more effective treatments for TN subtype. The results could be 
confounded by uncontrolled factors and need to be conﬁrmed in other oncology 
practices.
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OBJECTIVES: Docetaxel (D) is well recognized as ﬁrst-line chemotherapy in patients 
with metastatic prostate cancer (PC). To what extent gaps in treatment impact overall 
survival (OS) remains unknown. This study aimed to investigate the relationship 
between treatment gap and OS in a community practice. METHODS: Using the 
Georgia Cancer Specialist Database (2003–2008), patients with initial stage IV PC 
receiving D were identiﬁed and followed from the date of ﬁrst D use to the earlier of 
death or loss to follow-up. The three-month period prior to the ﬁrst D use was the 
baseline. A gap in treatment continuation was deﬁned as elapsed days between any 
adjacent treatment cycles of >60 days during follow-up. Kaplan-Meier curve was 
compared between patients with and without a gap using the log-rank test. The impact 
of treatment gap on OS was examined with multivariate Cox model by adjusting 
treatment cycles, age, comorbidity, baseline PSA, baseline bisphosphonate use, hor-
monal therapies and other chemotherapy during the follow-up. Sensitivity analysis 
(SA) was conducted with gap deﬁned as 90, 120 and 180 days. RESULTS: The study 
sample contained 47 patients, with mean age 75, average baseline PSA 296 ng/ml, 
48.9% treated with bisphosphonate at baseline, 53.3% treated with hormonal thera-
pies, and 29.8% treated with other chemotherapies during follow-up. Patients on 
average completed 10 cycles of docetaxel, with 7 (15%) patients experienced a treat-
ment gap. Median survival was 387 and 333 days for groups with and without gaps, 
respectively (P = 0.1654). The Cox model found no increased risk of death for the 
group with gap (HR = 0.80, P = 0.7189). Consistent results were found in SA. CON-
CLUSIONS: This analysis implied that allowing treatment gap in docetaxel treatment 
did not appear to impair OS for metastatic PC. The results could be confounded by 
some unadjusted factors, e.g., ethnicity and patients’ disease characteristics.
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OBJECTIVES: Docetaxel (D) is the ﬁrst-line chemotherapy in metastatic prostate 
cancer (PC). No study has assessed in a community practice, the relationship between 
treatment gaps and overall survival (OS). Using the International Oncology Network’s 
Treatment and Outcomes Database (2003–2008), this study aimed to evaluate this 
relationship in a large community practice network in US. METHODS: Patients with 
initial stage IV PC treated with D were followed from . the ﬁrst D use till the earlier 
of death or loss to follow-up. The three-month period prior to the ﬁrst D use was the 
baseline. A gap in treatment continuation was deﬁned as elapsed days between any 
adjacent treatment cycles >60 days. OS was compared between the groups with and 
without a gap using Kaplan-Meier curve. A Multivariate Cox model was used to 
examine the impact of treatment gap on OS with adjustment of potential confounders. 
Sensitivity analyses (SA) was conducted using different deﬁnitions to deﬁne the gap 
(90, 120, 180, and 270 days). RESULTS: Sixty-four patients were included in the 
analysis, with a mean age of 73, and a mean baseline PSA of 200 ng/ml. 32.8% were 
treated with bisphosphonate at baseline. A total of 23.4% were treated with hormonal 
therapies, and 39.1% were treated with other chemotherapies during follow-up, 
respectively. Twenty-three (36%) patients experienced a treatment gap. Median sur-
vival was 548 and 563 days for groups with and without a gap, respectively (P = 
0.6870). The Cox model showed no increased risk of death for the group with a gap 
compared to the group without a gap (HR = 0.940, p = 0.8847). SA showed consistent 
results. CONCLUSIONS: This analysis implied that allowing treatment gap in 
docetaxel did not appear to impair OS for in metastatic PC. Results could be con-
founded by unadjusted factors.
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OBJECTIVES: Docetaxel (D) is the ﬁrst-line chemotherapy in metastatic prostate 
cancer (PC). Not known is the relationship between the number of treatment cycles 
and overall survival (OS). Using the International Oncology Network’s Treatment and 
Outcomes Database (2003–2008), this study aimed to evaluate this relationship in a 
large community practice network in US. METHODS: Patients with initial stage IV 
PC receiving D were followed from the ﬁrst D use to the earlier of death or loss to 
follow-up. The three-month period prior to the ﬁrst D use was the baseline. Patients 
were split into two cohorts based on the mean treatment cycle count. OS survival was 
compared with Kaplan-Meier curve. A multivariate Cox model with potential con-
founders adjustment was used to evaluate the impact of cycle count on OS. Correlation 
robustness was assessed using sensitivity analyses (SA) with cycle number controlled 
as a count variable and a dummy variable (different thresholds 6 or 5). RESULTS: 
Sixty-four patients, mean age of 73 (ranging 54–96), had an average baseline PSA at 
200 ng/ml (0.7–1510 ng/ml). 32.8% were treated with bisphosphonate at the baseline. 
23.4% and 39.1% of the sample were treated with hormonal therapies and other 
chemotherapies during follow-up, respectively. The average number of treatment 
cycles was 7.1 (1–30), with 41 (64.1%) completing <7 and 23 (35.9%) patients 
completing ≥7 cycles. Median survival was 366 days for <7 group, and 577 days for 
≥7 group (p = 0.3505). The Cox model found a higher likelihood of survival for ≥7 
group (HR = 3.62, p = 0.0035). Similar results were found in SA. CONCLUSIONS: 
This analysis suggested that higher number of treatment cycles of D was associated 
with prolonged OS in metastatic PC. The results could be confounded by unadjusted 
factors, and the sample size was small. Therefore, no cause inference can be drawn 
based on this analysis.
